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BLOOD LEVELS OF 5-BROMO-2'-DEOXYURIDINE
IN INTRAPERITONEAL INFUSION FOR
DETERMINATION OF SISTER CHROMATID
EXCHANGE INDUCTION USING THE HPLC
ANGELO TURTURRO, NARENDRA P. SINGH,

JOHNNY BAZARE, JR., and RONALD W. HART
National Center for Toxicological Research
Jefferson, Arkansas 72079
ABSTRACT
A new technique was developed to measure the amount of 5-bromo-2 '-deoxy undine (BrdUrd), a thymidine
analogue, rapidly and conveniently in blood, and it was applied to measure the concentration ofBrdUrd
during the initiation of a paradigm for the labeling of DNA to measure the induction of sister chromatid
exchanges (SCE) by genotoxic agents. Radiolabelled BrdUrd was used and blood was drawn from the
abdominal aorta in pregnant Sprague-Dawley derived D rats. Using the hplc, the BrdUrd peak was easily
identifiable and separable from its metabolites. The BrdUrd level in the blood stabilized in 30 minutes,
and a level of about .4 mg% was enough to label the bone marrow and fetal tissue for SCE. Also, the
time course of the BrdUrd metabolites suggest a constant BrdUrd metabolism by the organism. Using
absorbance alone, blood levels of BrdUrd during paradigms of biological significance can be measured.
INTRODUCTION
The thymidine analogue 5-bromo-2'-deoxyuridine (BrdUrd), which
labels DNA permitting the measurement of the induction of sister
chromatid exhanges (SCE), is an important biological tool for estimation of genotoxicity in vivo (Turturro et al., 1982; Kram et al., 1980)
and in vitro (Perry, 1979; Takehisa and Wolff, 1977). It also has various
biological effects including: mutation (Fishbein et al., 1970), sensitization ofDNA lo radiation (Djordjevic and Szybalski, 1960), inhibition
of differentiation in developing systems (Stockdale et al., 1964; Clark,
1971) and the production of terata in mice (Skalko et al., 1971) and
hamsters (Ruffolo and Ferm, 1965). Quantitative interpretation of results
dependent upon the concentration of BrdUrd is limited, however,
because the compound is unstable in vivo, due to denomination as well
as deribosylation (Kriss and Revesz, 1962), both as a result of metabolism
and non-specific, chemical changes (Prusoff and Goz, 1975). Present
methods for the quantiiation of BrdUrd in vivo are tedious (Kriss and
Revesz, 1962; Fink and Adams, 1966; Kinget al., 1982) or insensitive
(Malz, 1980). To quantitate the levels of BrdUrd during measurement
of SCE induction in vivo using a newly developed infusion technique,
a simple hplc technique was developed which permits the separation
of the parent halogenated pyrimidine from its various products.
MATERIALAND METHODS
Animal Preparation: Pregnant Sprague-Dawley derived CD rats of
110-130 days of age at Day 20 of gestation were the test animals since
these animals are routinely used for In utero measurement of SCE
induction by intraperiioneal perfusion (Turturro et al., 1982).
After light etherization the abdomens of the animals were opened
with a midline incision. The abdominal aorta was cannulated with 2
cm of a heparinized saline filled PE-50 polyethylene tubing (ClayAdams, Parsippany, N.J.) at a level just anterior to the bifurcation of
the iliac arteries. A second catheter for the BrdLhd infusion, .03 inch
o.d. soft Tygon tubing (A. Daigger, Chicago, 111.), was placed inthe
abdominal cavity. The animal was then placed in a Bollman restrainer
cage (Bollman, 1948) and infused with a concentration of BrdUrd which
delivers a total dose of one gram/kg body weight ofBrdUrd over a
24 hour period in a 5% glucose solution at the rate of .78 ml/hr with
a perfusion pump (Harvard Perfusion Company, Mills,Mass.). This
is the dose used for measurement of SCE induction (Turturro et al.,
1982). As a marker, a tracer amount of radioactive BrdUrd, 10 Cis of
5-(2- C)-bromodeoxyuridine (44 mCi/mmol Sp. Act., New England
Nuclear, Boston, Mass.), was added to the infusion solution.
M
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At timed intervals, ten drops of blood were collected from the aortic
catheter. The cannula was cleared with a small amount of heparinized
saline afler every sampling. The results from three animals at twenty
days gestation were averaged.
AnalyticalTechnique: Ninety fds of blood, obtained as described above,
were added to 10 n\s of a 50% PCA solution, mixed and immediately
centrifuged in a Beckman Microfuge B for one minute. The PCA-soluble
fraction was recentrifuged, adjusted to approximately pH 5 with ION
NaOH and injected into a 20 n\ sample chamber of a Beckman Model
334 Density Gradient hplc. The column was eluted at 1.5 ml/min for
ten minutes with a 13°7o methanol (Fisher, Pittsburg, Pa., hplc grade)
in water solution on an Altex 4.6 mm X 25 cm ODS-Ultrasphere
column. Fractions were collected in scintillation vials.
The material eluted between one and 6.5 minutes was pooled together,
and the BrdUrd peak was collected from 7 to 8.5 minutes ofelution.
Analyticalgrade chemicals were purchased from Sigma Co. (St. Louis,
USA) except

where noted.

Radioactivity Measurement: The fractions containing the BrdUrd peak
from the hplc were dried in a 50 °C oven overnight, reconstituted to

one ml with distilled water and mixed. The PCA-insoluble residue was
redissolved in 0.5 ml Soluene (Packard, Downer's Grove, III.)and heated
at 50 °C overnight. The samples were then reconstituted to one ml. Blood
serum was separated from the remainder of the timed sample not used
for PCA solubilization (approximately 60 /il) by centrifugation on a
Beckman Microfuge B for one minute and diluted to one ml with distilled
water. Tenmis of Biofluor (New England Nuclear) were added to each,
and the samples were counted on a Searle Analytic 92 Liquid Scintillation counter. A quench curve was constructed for the PCA-insoluble
fraction by adding radioactivity to samples with different levels of
quenching as defined by the external standard ratio (ERS). An aliquot
ofinfusion solution was also counted with every experiment as a control for variability in dilution of the radioactive BrdUrd.
Absorbance Measurement: Peak areas were determined either by the
Altex Model C-R1A integrator of the Model 334 hplc (at .2 absorbance
units full scale at 279 nin) or by weighing of peaks cut from the
integrator profile. Repeated measures of a 1 nanomole standard of
Brdurd were reproducible lo within 2%. Peaks areas were quantitated
byinjection of known standard amounts of BrdUrd and also by quantitation of the radioactivity of the collected peak when tracer amounts
of the radioactive species was used. Values as low as 50 picomoles could
be estimated from absorbance alone.
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RESULTS
At 1.5 ml/min using a solvent of 13% methanol:water, BrdUrd
chromatographed as a single peak with a retention time of7.6 minutes.

The material in this peak co-chromatographed with pure BrdUrd for
a number of different retention times (varied by both modifying the
rate of the solvent and varying the percent of methanol
to 13%) and was identical in ultraviolet spectrum with pure

from 6
BrdUrd
dissolved in 13% methanohwater solution (Figure 1). The BrdUrd peak
was stable in infusion solution for at least two hours when kept in a
plastic microtube (Figure 2). The products associated with BrdUrd infusion chromatograph with different retention times than the parent
material. This is demonstrated for the major known metabolites of
BrdUrd, uracil and 5-bromouracil (Kriss and Revesz, 1962) in Figure
3, as well as for 5-bromouridine. Thus, the material that eluted from
one minute (when the material from the injected sample first passes
through the column) to 6.5 minutes, just before the BrdUrd peak, was
pooled into one fraction and denoted BrdUrd metabolites. Also,
injected radioactivity could be quantitatively accounted for ifthe two
fractions were added together. Comparison of hplc profiles of the PCAsoluble fraction ofblood in infused animals (shown after 30 minutes
in Figure 4A) and control profiles (Figure 4B), shows the BrdUrd peak
clearly separated from the normal constituents of the fraction unlike
some of BrdUrd metabolites (such as uracil) which are difficult to determine accurately from absorbance alone since they are submerged in a
number of peaks at early retention times.
Total radioactivity as a function of time in the PCA-soluble
fraction of blood, given as the amount ofBrdUrd to which the radioactivityis equivalent, and serum are shown in Figure 5. The time course
of the radioactivity contained in the PCA-insoluble fraction is also
included. Taken together, the whole blood level of BrdUrd and its
metabolites can be determined. These data demonstrate an increase in
radioactivity with time, with relatively less of an increase in serum than
in the PCA-insoluble fraction. The smallest increase is observed in the
PCA-soluble blood fraction. In the last, the blood levels of BrdUrd
(as defined by both absorbance at 279 nm and radioactivity of the
BrdUrd peak) during infusion are given at Figure 6. The BrdUrd level
reaches equilibrium after approximately 30 minutes and remains relativelyconstant, while the level of BrdUrd metabolites in blood increases
linearly as a function of time.
flow

Figure 2.

BrdUrd

profile after two hours.

Figure 3. HPLC profile of BrdUrd (a) and uracil (b), 5-bromouraeil
(c) and 5-bromouridine (d).

Figure 1. Ultraviolet spectrum ofmaterial from the BrdUrd peak and
BrdUrd in 13% methanol: water. Peak I = BrdUrd in 13%
methanohwater; peak II = directly from column.

Figure 4. HPLC profile of the PCA-soluble fraction of a catherterized
rat a) 30 minutes after the start of infusion and b) control (before onset
of infusion). Arrow denotes BrdUrd peak, asterisk and dot denote
metabolite peaks.
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The concentration ofBrdUrd plateaus

at approximately

140 ngms/20

/ils of the PCA-soluble fraction. This is approximately .35 /ignis per
90 /*ls which converts to .39 mg°7o of free BrdUrd in whole blood. This
level is sufficient to label clearly the chromosomes ofcells in metaphase
in maternal bone marrow and to provide enough material for
placental transfer to label metaphases in fetal cells (Turturro et al., 1982).

DISCUSSION
This technique is able to rapidly and conveniently separate BrdUrd
from its metabolites in the blood with minimum treatment ofthe blood
sample. Other methodologies require either extensive separation from
the blood and tedious procedures (Kriss and Revesz, 1962; Fink and
Adams, 1966; Kingetal., 1982) or require more than 20 gms ofmaterial
for detection (Matz, 1980), which is clearly too insensitive for measuring blood BrdUrd levels.

Figure 5. Radioactivity levels in the PCA-soluble (dots) and PCAinsoluble (squares) blood fractions and blood serum (diamonds). Bars

are standard deviations.

The data inthis paper are the first in vivomeasurement of BrdUrd
blood levels after initiating a continuous infusion paradigm successful
for measurement of SCE. The blood levels ofBrdUrd using pellet implantation ofBrdUrd (Kinget al., 1982) initiallyrise precipitously for
up to 7 hours to high values and then fall to very low levels, with a
mean close to the BrdUrd concentration measured here. The data
presented here demonstrate that the intraperitoneal application of
BrdUrd for SCE visualization results in a fairly stable level of BrdUrd
inless than thirty minutes. Also, intraperitoneal administration seems
to provide a steady rise in BrdUrd level up to a plateau. BrdUrd concentration can influence the number ofSCE (Wolff and Perry, 1974)
so, in avoiding these violent fluctuations in levels, it is a reasonable
assumption that this approach will enhance accurate quantitation of
SCE in vivo.
Ablood level of.39 mg% is about a tenth of that used to determine
SCE induction in vitro (Perry, 1979; Takehisa and Wolff, 1977). In
vitro determinations usually exhibit a higher frequency of "spontaneous" SCE, i.e., control SCE values, than in vivo, which now can
be seen as a direct result of the higher BrdUrd level in vitro.
The PCA-soluble fraction, serum and the PCA-insoluble fraction all
accumulate radioactivity with time in a fairly linear fashion from
thirtyminutes onward. The rate ofaccumulation increases with the proportion of BrdUrd derivatives not in solution, suggesting that the
accumulations result from a constant BrdUrd level, i.e., the free BrdUrd,
which is metabolized and bound to protein and other blood components.
The amount of radioactivity in the PCA-soluble fraction is derived from
two components, the level of BrdUrd, which is fairly stable, and the
level of other products associated with BrdUrd infusion, which are
linearly increasing. Since the liver quickly metabolizes BrdUrd (Kriss
and Revesz, 1962) most of the products associated with the infused
material are probably the results of metabolic rather than non-specific
breakdown. The linear increase of products with time suggests that either
infused degradation products are accumulating at a constant rate or
BrdUrd metabolism is going on at a constant rate with residue of
metabolism increasing in the blood. The undetectable levels of
breakdown products in the infusion solution, even after two hours, weigh
against the first explanation. Therefore, the level of the metabolites seem
to be some overall measure ofthe accumulated metabolism of BrdUrd.
BrdUrd metabolism, and its correlate, thymidine metabolism, may
therefore be evaluated cumulatively in the organism, an important factor
in studies of DNA and DNA metabolism.
Abenefit of the technique presented is that it is sensitive enough to
permit the measurement of biologically significant levels of BrdUrd in
blood without using radioactivity. Measuring the BrdUrd level by absorbance allows determinations to be made quickly without the cost
and inconvenience of using radiolabeled species ifmetabolite estimation is not important. Coupled with radioactivity, the technique
permits the easy determination of the levels of BrdUrd and its
metabolites, important in the evaluation of the biological effects of the
agent and in understanding the results of its use.
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